Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brown Fat's hidden role in fatty liver disease under investigation

NCT ID NCT07825467

Knowledge-focused Sponsor: Renmin Hospital of Wuhan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers at Renmin Hospital of Wuhan University are studying whether brown fat activity is linked to nonalcoholic fatty liver disease. They analyze stored PET/CT scans and blood samples from 96 people who had clinically indicated scans. The goal is to find blood proteins that differ across groups with high, medium, and low brown fat activity. No new treatments or scans are given.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If researchers find blood proteins that track with brown fat activity, those proteins could become targets for future treatments or tests for fatty liver disease.
What could go wrong
This observational study cannot prove cause and effect, and it relies on existing scans and blood samples from a small group at one hospital. The findings may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

96 people

The number who actually took part.

Started

Jan 2026

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults aged 18 to 80 years who had previously undergone 18F-FDG PET/CT examination for clinical purposes were recruited. Existing PET/CT imaging data were used to assess brown adipose tissue activity, and participants were categorized into high, intermediate, and low BAT activity groups according to BAT SUVmax. Peripheral blood samples and relevant clinical data were collected for analysis. No additional PET/CT examination was performed for research purposes.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients who had undergone clinically indicated 18F-FDG PET/CT examination. * Willing and able to provide written informed consent and comply with the study procedures. * No long-term use of medications such as glucocorticoids or lipid-lowering drugs; no smoking or excessive alcohol consumption (alcohol intake \<20 g/day). * High BAT activity group: BAT SUVmax ≥2.0, with clear BAT activation in the cervical, shoulder, or supraclavicular regions on PET/CT. * Intermediate BAT activity group: 1.0 ≤ BAT SUVmax \<2.0. * Low BAT activity group: BAT SUVmax \<1.0 or no detectable BAT distribution on PET/CT. Exclusion Criteria: * Use of medications affecting metabolism within the previous 3 months, such as beta-blockers or thyroid hormones. * Contraindications to PET/CT examination, such as claustrophobia or contrast-agent allergy. * Pregnancy or breastfeeding.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nonalcoholic fatty liver disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nonalcoholic fatty liver disease

Contacts and locations

Locations

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, 430060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.